Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2025 (Specifically November 18, 2025)
Context: This filing incorporates by reference a press release regarding clinical progress for the company's drug candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes
Clinical Development Update: The company announced a significant clinical milestone involving its drug candidate, Namodenoson. A patient with advanced liver cancer treated with Namodenoson achieved a 9-year survival with a complete cure.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the long-term survival and complete cure in an advanced liver cancer patient as a key data point for Namodenoson.
Risks and Contingencies: The filing text does not explicitly detail new risks, contingencies, or unusual items beyond the standard incorporation of the press release. No specific financial guidance or future outlook numbers are provided in this document.
Investor Verification Checklist
- Verify the full details of the press release (Exhibit 99.1) regarding the 9-year survival case study.
- Confirm the current clinical trial phase and regulatory status of Namodenoson for liver cancer.
- Review the company's most recent Form 20-F or quarterly reports for updated financial liquidity and cash burn rates, as this filing contains no financial data.
- Assess the statistical significance of a single patient case study versus broader clinical trial data.